Close Menu

Research & Discovery

The latest research news in genetics and genomics.

The company posted $1.3 million in revenues with OVA1 test sales up 82 percent to 3,602 and revenue per test down 8 percent to $345.

A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.  

 

The German company offers rare disease genetic tests and services for clinical applications, as well as to support drug discovery and development programs.

The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.